CXCL10-LACTC1/C2 Expressing Mesenchymal Stem Cell Conditioned Medium Attenuates TNF-α-Induced Gene Expressions and

Kaya Molo1,2, Ruken Ege1, Kübra Ati̇k1

  • 1Faculty of Science and Letters, Department of Molecular Biology and Genetics, Yıldız Technical University, Istanbul, 34220, Turkey.

Inflammation
|May 22, 2026
PubMed

Insights

Engineered mesenchymal stem cells (MSCs) expressing CXCL10 showed enhanced immunomodulatory functions. This strategy offers potential for treating inflammation in atherosclerosis and vascular injury.

Area of Science:

  • Immunology
  • Regenerative Medicine
  • Vascular Biology

Background:

  • Infectious diseases worsen atherosclerosis via sustained inflammation and elevated cytokines like CXCL10.
  • CXCL10 recruits immune cells, promoting endothelial dysfunction and disease progression.
  • Mesenchymal stem cells (MSCs) secrete CXCL10, but its role in MSC immunomodulation is unclear.

Purpose of the Study:

  • To investigate if CXCL10 signaling modulates MSC-mediated immunoregulation.
  • To engineer MSCs for localized, sustained CXCL10 presentation.
  • To assess the impact on MSC immunomodulatory mediator expression and endothelial cell responses.

Main Methods:

  • Genetically engineered Wharton's jelly-derived MSCs (WJ-MSCs) to express a membrane-anchored CXCL10-Lactadherin C1/C2 fusion protein (CXCL10-LACTC1/C2).
  • Cultured engineered MSCs and analyzed immunoregulatory mediator expression (IDO1, TGF-β1, IL4I1).
  • Assessed conditioned medium from engineered MSCs on TNF-α-stimulated human umbilical vein endothelial cells (HUVECs), evaluating inflammatory markers and cell viability.

Main Results:

  • CXCL10-LACTC1/C2-expressing MSCs showed increased expression of IDO1, TGF-β1, and IL4I1.
  • Conditioned medium from engineered MSCs attenuated TNF-α-induced inflammatory responses in HUVECs.
  • Key endothelial activation and homeostasis markers (ICAM-1, PECAM-1, KDR, vWF, NRF2) were modulated, and HUVEC viability improved.

Conclusions:

  • CXCL10 signaling can enhance MSC immunomodulatory programming.
  • Membrane-anchored CXCL10 expression in MSCs boosts their therapeutic potential.
  • Findings support MSC-based or cell-free therapies for CXCL10-driven inflammation in vascular diseases.